Apotex Pharmaceutical Holdings’ acquisition by an affiliate of funds advised by SK Capital Partners has closed. The company also appointed Allan Oberman as president and CEO and member of the board of Apotex.
Oberman brings four decades of experience in corporate leadership to Apotex, including 20 years in the pharmaceutical industry. Most recently, he served as CEO of Concordia International and CEO of Sagent Pharmaceuticals. Prior to these positions, he served as president and CEO of Teva Canada (formerly Novopharm Limited), COO of Teva International Group, president of Teva EMIA and president and CEO of Teva Americas Generics. Oberman has almost three decades of corporate governance experience, having served on numerous boards, including as chairman of the Canadian Generic Pharmaceutical Association, and vice-chairman of the U.S. Association for Accessible Medicines.
“As a competitor to Apotex for many years, I am very familiar with the company and have admired its people, long-term track record of innovation and commitment to making medicines affordable to patients in Canada and worldwide,” Allan Oberman, president and CEO of Apotex, said. “I’m excited to join the team and build on that legacy.”
“We welcome Allan to the Apotex team. His experience leading major Canadian and international pharmaceutical companies and delivering enhanced shareholder value will benefit Apotex as we grow into a Canadian-based global health company,” Aaron Davenport, chairman of the board of Apotex and managing director at SK Capital, said. “SK Capital looks forward to working with Apotex as it moves into its next phase of growth, leveraging its iconic brand, broad product portfolio, international presence and skilled team.”
